Company Overview
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company dedicated to the development of antibiotics designed to treat bacterial infections within the United States market. The company functions within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies its reliance on research and development to create novel therapeutic agents rather than traditional manufacturing or sales of established products. Currently, the enterprise maintains a market capitalization of $10.73M and employs a workforce of 4 individuals, reflecting a highly lean operational structure typical of early-stage biotech firms. These figures indicate that the company is in a pre-revenue or very early commercialization phase where market capitalization is derived primarily from investor expectations regarding the success of its lead candidate, ibezapolstat, rather than current sales performance, as evidenced by the lack of reported annual revenue data.
Financial Health
The company reports a Net Income (TTM) of $-7,966,538, while Revenue (TTM) and EBITDA are listed as N/A, revealing a cost structure where expenses significantly outweigh any current income generation. The absence of reported revenue suggests the business is still in an investment phase, where the gap between revenue and net income is entirely attributable to the high costs associated with clinical trials and drug development rather than operational inefficiencies. Free Cash Flow stands at $-4,291,853, indicating that the company is burning cash rapidly to fund its operations and clinical progress, which limits immediate financial flexibility but is a standard characteristic of clinical stage biotechnology entities. All three margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a metric that in this context reflects the lack of commercial sales volume rather than a failure to cover variable costs. The balance sheet shows a Cash position of $7.56M against N/A for Debt, suggesting the company is not currently leveraged with significant interest-bearing obligations. This liquidity profile allows the firm to fund its current burn rate without immediate recourse to external financing or asset liquidation. The Current Ratio is 3.18, a figure that indicates robust short-term liquidity and a strong ability to meet obligations due within one year using existing current assets. Finally, the Return on Equity is -270.8% and the Return on Assets is -87.6%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate significant losses rather than profits, a common outcome during the expensive clinical development stages of a novel mechanism of action targeting the polymerase IIIC enzyme.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to the company's losses, while the Forward P/E is reported as -1.71, implying that the market is pricing in continued earnings contraction or that valuation is based on future projected earnings that have not yet materialized in financial statements. The Price to Book ratio is 1.68, which indicates that the company's current market valuation is trading at a 68% premium over its book value, reflecting investor confidence in the potential value of its intellectual property despite current losses. The Price to Sales and EV/EBITDA metrics are both N/A, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable at this stage of development where no revenue or earnings exist to calculate these ratios. The 52-week price range spans from a low of $1.33 to a high of $21.00, providing a historical context for price volatility and investor sentiment swings over the past year. The current price sits somewhere within this range, but without the specific current price listed in the available facts, the exact percentage distance from the high or low cannot be calculated, though the wide spread of $19.67 between the high and low demonstrates significant price instability. The Beta is -1.16, a negative value that indicates the stock's price moves inversely to the broader market trends and suggests extreme volatility that does not correlate with standard market risk factors.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, as the company has not yet generated sufficient revenue history to calculate year-over-year growth rates, meaning there is no historical data to compare current performance against prior periods. Because the company has not reached profitability, the concept of a dividend yield and payout ratio is not applicable, with the Dividend Yield listed as N/A and the Payout Ratio at 0.0%, confirming that the company reinvests all available resources and potential earnings back into research and development rather than distributing income to shareholders. This zero payout ratio is sustainable given the lack of net income, as the firm is in a stage where capital preservation and funding clinical trials take precedence over shareholder distributions. The overall growth and income profile is characterized by a lack of historical financial growth metrics and a complete absence of dividend income, focusing instead on the high-risk, high-potential nature of developing a novel antibiotic candidate.